Sprint Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Sprint Bioscience has a total shareholder equity of SEK27.8M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK62.4M and SEK34.6M respectively.
Key information
0%
Debt to equity ratio
kr0
Debt
| Interest coverage ratio | n/a |
| Cash | kr49.93m |
| Equity | kr27.77m |
| Total liabilities | kr34.60m |
| Total assets | kr62.38m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: SPRINT's short term assets (SEK57.9M) exceed its short term liabilities (SEK34.6M).
Long Term Liabilities: SPRINT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SPRINT is debt free.
Reducing Debt: SPRINT currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SPRINT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SPRINT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.3% per year.